Q2 EPS Estimates for Connect Biopharma Cut by HC Wainwright

Posted by Editorial Team on Apr 6th, 2025

Connect Biopharma Holdings Limited (NASDAQ:CNTB – Free Report) – Equities researchers at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for shares of Connect Biopharma in a report issued on Tuesday, April 1st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.27) per share for the quarter, down from their previous forecast of ($0.26). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2025 earnings at ($0.29) EPS.

Connect Biopharma Stock Performance

Shares of Connect Biopharma stock opened at $0.63 on Friday. Connect Biopharma has a 1 year low of $0.51 and a 1 year high of $2.29. The company’s fifty day simple moving average is $0.85 and its 200-day simple moving average is $1.05.

Institutional Trading of Connect Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of CNTB. Catalina Capital Group LLC bought a new stake in shares of Connect Biopharma in the fourth quarter valued at about $66,000. Choreo LLC acquired a new position in Connect Biopharma in the 4th quarter valued at approximately $204,000. Finally, Callan Capital LLC lifted its position in shares of Connect Biopharma by 91.3% in the 4th quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after acquiring an additional 38,177 shares during the period. 58.72% of the stock is currently owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.